论文部分内容阅读
目的观察和肽素联合N末端脑钠肽前体(NT-pro BNP)对慢性心力衰竭(CHF)患者严重程度及近期预后的相关性分析。方法 80例CHF患者作为CHF组,40例健康体检者作为对照组,两组均行和肽素以及NT-pro BNP检查,比较CHF组与对照组和肽素以及NT-pro BNP的水平差别,不同NHYA心功能分级患者两指标的变化,根据患者随访结果再次分为事件组和非事件组,并进行组间两指标的比较。结果 CHF组患者和肽素与NT-pro BNP水平(4497.50±1564.31)、(6970.10±1054.33)pg/ml明显高于对照组(1306.42±94.72)、(124.06±33.55)pg/ml(P<0.05);随着心功能分级的升高,患者和肽素水平和NT-pro BNP水平也明显升高(P<0.05);事件组患者和肽素水平和NT-pro BNP水平(4579.82±1153.43)、(8143.66±2202.17)pg/ml明显高于非事件组(2054.73±984.65)、(944.83±157.26)pg/ml(P<0.05)。结论和肽素联合NT-pro BNP检测有助于临床医生对CHF患者的病情严重程度以及预后情况做出早期预测,对于疾病诊断以及治疗具有重要意义。
Objective To investigate the correlation between copeptin and NT-pro BNP on the severity and prognosis of patients with chronic heart failure (CHF). Methods Eighty CHF patients were selected as CHF group and 40 healthy subjects as control group. Copeptin and NT-proBNP were examined in both groups. The levels of copeptin and NT-pro BNP in CHF group were compared with those in control group. The changes of two indexes in patients with different NHYA heart function grading were divided into incident group and non-incident group again according to the follow-up results of the patients, and the comparison of two indexes was made between groups. Results Compared with control group (1306.42 ± 94.72), (124.06 ± 33.55) pg / ml (P <0.05), the levels of copeptin and NT-pro BNP in CHF group were significantly higher than those in control group (4497.50 ± 1564.31, 6970.10 ± 1054.33) pg / ). The copeptin level and NT-pro BNP level were also significantly increased with the increase of heart function classification (P <0.05). The levels of copeptin and NT-pro BNP in the event group (4579.82 ± 1153.43) , (8143.66 ± 2202.17) pg / ml was significantly higher than that of non-event group (2054.73 ± 984.65) and (944.83 ± 157.26) pg / ml, respectively (P <0.05). Conclusions The combination of copeptin and NT-pro BNP can help clinicians make early prediction of the severity and prognosis of CHF patients, which is of great significance for the diagnosis and treatment of diseases.